ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Oct 23, 2017
Restasis Patent Protection Weighing on Shares of Allergan
Image Source: Allergan. We have witnessed numerous examples over the years of biotech/pharma companies selling-off over fears of the length of patent protection on an essential product. The concern is well-founded--if the company relies on the product for a significant portion of sales, it may be challenging to replace, especially if the clinical pipeline is relatively bereft of viable next-generation products. We believe the recent sell-off in the shares of Allergan may now be wholly factoring in the loss of patent protection of one of its core assets in Restasis, and the equity may not be getting enough credit for its highly diversified revenue stream.
Oct 20, 2017
GE Cuts Guidance, All Eyes Turn to November 13
Image Source: darkon_turaas. On October 20, General Electric slashed its guidance for earnings and cash flow from operating activities after reporting another weak quarter. Could the dividend be next on the chopping block? Management will update investors on company strategy and its 2018 framework Monday, November 13, an event to which we’ll be paying close attention.
Oct 20, 2017
The Market Loves PayPal; Shares Now $70+
Image Shown: PayPal's stock has been a huge winner in the Best Ideas Newsletter portfolio. Payments processor PayPal reported fantastic third-quarter results and raised its full-year guidance for the third time in as many quarters. Shares are surging.
Oct 19, 2017
Kinder Morgan’s Dividend Growth For Next Year Is Achievable; Here's Why
Image Source: Roy Luck. After its infamous dividend cut, Kinder Morgan is getting things back on track. We applaud management for its ability to bounce back from a tumultuous energy-resource pricing environment.
Oct 19, 2017
Reimbursement Uncertainty Weighs on DaVita
Image Source: DaVita. DaVita has been left out in the cold with its share price losing ground in 2017 due to continued fears over reimbursement of care.
Oct 19, 2017
IBM's Third Quarter Offers Some Relief
Image Shown: IBM rallies back after third-quarter results October 18. IBM has been shunned by investors since it bailed on its operating earnings per share target of $20 a few years ago. The market, however, was recently relieved that IBM reiterated its full-year 2017 expectations calling for operating earnings per share of at least $13.80. Many are hoping for a comeback.
Oct 17, 2017
Netflix's Third Quarter Shows Free Cash Burn, More Debt
The Netflix app is displayed alongside other streaming media services on the homepage of a Roku Streaming Stick. (Photo credit: Matthew Keys / Flickr Creative Commons)Netflix is burning through free cash and the company’s balance sheet is ballooning with debt. The junk-rated company continues to attract buyers in this frothy stock market, however.
Oct 14, 2017
Euphoria Running Rampant: Investigating Some of the Hottest Names Around
Image Source: Tesla Roadster. As we march forward in what Morgan Stanley has dubbed a bull market of “epic proportions,” euphoria appears to be at levels perhaps not seen since the dot-com bust of the early 2000s. Let’s take a look at some of the “hottest” names on the market.
Oct 5, 2017
Competitive Pressures Not Going Away for Teva
Image Source: Mylan. The end of the patent life of a lucrative product can often lead to significant legal strife as aspiring biosimilar equivalents jockey for exclusivity. We have found the recent aggressive move by Mylan noteworthy in our ongoing coverage of Teva’s recent struggles. On a separate but related note, the settlement between Amgen and Abbvie underscores the volatile nature of maneuvers conducted in order to extend the patent life of a highly successful product.
Oct 5, 2017
The Legal Battle Between Regeneron and Amgen Heats Up
Image Source: Regeneron. The legal battle between two of the titans of the biotech world heated up further with a recent ruling overturning the injunction of a critical asset. We are updating our thesis in light of current events.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.